To review the current data on bispecific antibodies (BsAbs) in the treatment of multiple myeloma (MM), emphasizing their significance in improving outcomes for patients with limited treatment options.
Key Findings:
BsAbs show promising efficacy in heavily pre-treated MM patients, particularly those refractory to existing therapies, indicating a potential shift in treatment paradigms.
BCMA and GPRC5D are key targets for BsAbs, with BCMA being a well-established target and GPRC5D emerging as a novel target, which may offer new therapeutic avenues.
Talquetamab received FDA accelerated approval in August 2023, underscoring the rapid advancement of GPRC5D-targeting therapies and their potential impact on patient outcomes.
Interpretation:
The use of BsAbs represents a significant advancement in MM treatment, offering new hope for patients with limited options due to treatment resistance, and may redefine therapeutic strategies.
Limitations:
The long-term efficacy and safety of BsAbs in diverse patient populations remain to be fully established, necessitating further research.
Potential for antigen shedding and the development of resistance to targeted therapies may limit effectiveness, highlighting the need for combination strategies.
Conclusion:
Bispecific antibodies are a promising addition to the treatment landscape of multiple myeloma, with ongoing research needed to optimize their use, explore combination strategies, and address limitations.
